Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Melissa BadamoMyelofibrosis | April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Read More
Blood Cancers Today Staff WritersMyelofibrosis | April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Melissa BadamoMyeloproliferative Neoplasms | March 29, 2024
Dr. Harrison discusses her current clinical research, building community with MPN Voice, and her journey into hematology.
Leah SherwoodMyelodysplastic Syndromes | March 28, 2024
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Patrick DalyMyelofibrosis | March 22, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Leah SherwoodMyelofibrosis | March 4, 2024
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyelofibrosis | March 1, 2024
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Sangeetha Venugopal, MDMyelofibrosis | March 4, 2024
Venugopal highlights myelofibrosis research at ASH 2023.
Andrew Kuykendall, MDPolycythemia Vera | December 13, 2023
Real-world databases lent insight into how often patients with PV experience thromboembolic events.
Haifa Kathrin Al-Ali, MDMyelofibrosis | March 4, 2024
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Benjamin Rolles, MDMyeloproliferative Neoplasms | December 13, 2023
Worse survival in single-hit TP53 patients was mainly driven by bone marrow fibrosis.
Melissa BadamoMyelofibrosis | December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Emily HayesPolycythemia Vera | December 11, 2023
Knowing who is at high risk in the near term could make it easier to conduct trials of anti-thrombotic therapies.
Editorial Board